Scholarlink

Background <p>In late 2022, Beijing, China saw a large-scale BF.7 Omicron variant breakthrough infection. However, the impact of COVID-19 vaccines on elderly breakthrough-infected patients’ antibodies and immune cells response was unclear.</p> Methods <p>We recruited 329 inpatients over 65 with BF.7 breakthrough infections. We analyzed the link between vaccination and survival in 67 sampled patients, investigating changes in antibody levels, cytokine profiles, as well as immune phenotypes.</p> Results <p>Experiments revealed that while vaccination could raise antibody levels in the elderly, it showed no significant neutralizing activity against the emerging COVID-19 variant XBB. Flow cytometry showed vaccination increased the proportion of CD4<sup>+</sup> senescent T cells. Moreover, we found that elevated frequencies of CD4<sup>+</sup> Tsens cells were associated with reduced antigen-specific CD4<sup>+</sup> T cell activation, diminished IL-2 production, and lower proportions of Tfh cells, which ultimately leading to impaired neutralizing antibody production, particularly against new emerging variants.</p> Conclusions <p>We found the immunological efficacy of inactivated vaccines in elderly patients is influenced by the proportion of CD4<sup>+</sup> senescent T cells. Future elderly vaccination strategies need optimization in dose number and timing, and future vaccine design should aim to minimize the generation of CD4<sup>+</sup> senescent T cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role of senescent CD4+ T cells in breakthrough infection of the new variant strain of SARS-CoV-2 in elderly patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Zhaoyuan Liang,
  • Hua Zhang,
  • Lu Xu,
  • Nan Li,
  • Zhongnan Yin,
  • Yongchang Sun,
  • Ning Shen,
  • Zhengyang Guo,
  • Yuqing Wang,
  • Lixiang Xue,
  • Jie Zhang,
  • Lin Zeng,
  • Jianling Yang,
  • Siyan Zhan

摘要

Background

In late 2022, Beijing, China saw a large-scale BF.7 Omicron variant breakthrough infection. However, the impact of COVID-19 vaccines on elderly breakthrough-infected patients’ antibodies and immune cells response was unclear.

Methods

We recruited 329 inpatients over 65 with BF.7 breakthrough infections. We analyzed the link between vaccination and survival in 67 sampled patients, investigating changes in antibody levels, cytokine profiles, as well as immune phenotypes.

Results

Experiments revealed that while vaccination could raise antibody levels in the elderly, it showed no significant neutralizing activity against the emerging COVID-19 variant XBB. Flow cytometry showed vaccination increased the proportion of CD4+ senescent T cells. Moreover, we found that elevated frequencies of CD4+ Tsens cells were associated with reduced antigen-specific CD4+ T cell activation, diminished IL-2 production, and lower proportions of Tfh cells, which ultimately leading to impaired neutralizing antibody production, particularly against new emerging variants.

Conclusions

We found the immunological efficacy of inactivated vaccines in elderly patients is influenced by the proportion of CD4+ senescent T cells. Future elderly vaccination strategies need optimization in dose number and timing, and future vaccine design should aim to minimize the generation of CD4+ senescent T cells.